– Lorundrostat, a highly selective aldosterone synthase inhibitor, demonstrated robust, double-digit reduction in systolic blood pressure (BP) with a well-tolerated profile –
– Enhanced reduction in systolic BP seen in individuals with elevated body mass index (BMI) –
– Robust trial design and results led to lorundrostat being first of new class, aldosterone synthase inhibitors, to start pivotal clinical program in hypertension –
RADNOR, Pa., Sept. 10, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease and other diseases driven by abnormally elevated aldosterone, today announced that full results from the Target-HTN Phase 2 trial of lorundrostat, a highly selective aldosterone synthase inhibitor, in individuals with uncontrolled hypertension (uHTN) and treatment-resistant hypertension (rHTN) were published in the Journal of the American Medical Association (JAMA).
"Despite the multitude of currently available treatments, half of all patients treated for hypertension are not able to reach their blood pressure goal. Up to 25 percent of all people with hypertension exhibit abnormal aldosterone levels," said Luke Laffin, M.D., lead investigator and co-director of the Center for Blood Pressure Disorders in the Heart, Vascular & Thoracic Institute at Cleveland Clinic. "Importantly, the Target-HTN study of lorundrostat demonstrated data compelling enough to warrant its advancement into late-stage clinical trials, representing a first-in-class milestone that will further the goal of understanding a new way of treating uncontrolled and treatment-resistant hypertension that takes the underlying causes into account."
In the Target-HTN Phase 2 trial, lorundrostat demonstrated a significant, double-digit reduction in SBP with a well-tolerated profile in the intent-to-treat population of uHTN and rHTN. Subjects with an elevated BMI, and participants taking a thiazide-type diuretic, demonstrated an enhanced reduction in SBP.
The publication notes that blood pressure guidelines recommend similar medication combinations for most patients, regardless of underlying comorbidities or the dominant underlying contributor to hypertension, and that new treatments are needed as management of blood pressure in the U.S. is relatively poor, and hypertension remains a major cause of excess morbidity and mortality.
"We are gratified that JAMA chose to highlight our Target-HTN Phase 2 trial results. These results demonstrated potentially transformative blood pressure reduction in difficult-to-treat hypertension, particularly so in obese individuals, who are known to have elevated aldosterone and suffer from excess cardiovascular morbidity and mortality," stated David Rodman, M.D., Chief Medical Officer for Mineralys. "We believe this trial confirms the link between obesity, excess aldosterone production and hypertension. Based on the beneficial response observed in Target-HTN, our recently initiated pivotal program lays the groundwork to facilitate identification of patients who may benefit from an aldosterone-targeted therapy like lorundrostat."
The trial results support further study of lorundrostat as a treatment for uHTN, including the Company's ongoing pivotal development program for lorundrostat to treat uHTN and rHTN. Under this program, the Company is currently enrolling subjects in the pivotal Advance-HTN trial and expects to initiate the pivotal Launch-HTN trial in the second half of the year, with topline data expected in the first half of 2024 and mid-2025, respectively.
The Target-HTN (NCT05001945) Phase 2 proof-of-concept trial was a randomized, double-blind, placebo-controlled, dose-ranging, multicenter trial conducted in the U.S. The trial was designed to evaluate the safety, efficacy, tolerability and dose response of orally administered lorundrostat for the treatment of uHTN and rHTN when used as add-on therapy to stable background treatment of two or more antihypertensive agents in 200 male and female subjects 18 years of age or older. Five active doses of lorundrostat (12.5mg once daily QD, 50mg QD, 100mg QD, 12.5mg twice daily [BID], and 25mg BID) were compared to placebo in hypertensive subjects. Pharmacokinetic, pharmacodynamic and response data established that a once-daily dosing regimen was optimal. Adverse events observed were a modest increase in serum potassium, decrease in estimated glomerular filtration rate, urinary tract infection and hypertension with one serious adverse event possibly related to study drug being hyponatremia.
— Lorundrostat 是一種高選擇性的醛固酮合成酶抑制劑,其收縮壓 (BP) 顯著降低了兩位數,耐受性良好 —
— 體重指數 (BMI) 升高者收縮壓進一步降低 —
— 穩健的試驗設計和結果使lorundrostat成爲首個新類別的醛固酮合成酶抑制劑,開始了高血壓的關鍵臨床項目 —
賓夕法尼亞州拉德諾,2023年9月10日(GLOBE NEWSWIRE)—— Mineralys Therapeutics, Inc. (納斯達克股票代碼:MLYS)今天宣佈,在《美國醫學會雜誌》(JAMA)上發表了高選擇性醛固酮合成酶抑制劑 lorundrostat 在未控制高血壓(uHTN)和耐藥高血壓(rHTN)患者中的 Target-HTN 2 期試驗的全部結果。
“儘管目前有多種治療方法,但在接受高血壓治療的所有患者中,有一半無法達到血壓目標。在所有高血壓患者中,多達25%的人表現出醛固酮水平異常。” 克利夫蘭診所心臟、血管和胸部研究所血壓疾病中心首席研究員兼聯合主任盧克·拉芬醫學博士說。“重要的是,對lorundrostat的Target-HTN研究表明,lorundrostat的數據足夠令人信服,足以保證其進入後期臨床試驗,這是同類首創的里程碑,它將進一步實現了解一種考慮到根本原因的治療失控和耐藥性高血壓的新方法的目標。”
在靶向HTN和rhTN2期試驗中,lorundrostat在意向治療的uhTN和rhTN人羣中顯示SBP顯著降低了兩位數,耐受性良好。體重指數升高的受試者和服用噻嗪類利尿劑的受試者表現出SBP的降低幅度增強。
該出版物指出,血壓指南建議大多數患者使用類似的藥物組合,無論潛在的合併症或高血壓的主要潛在因素如何,並且由於美國的血壓管理相對較差,高血壓仍然是發病率和死亡率過高的主要原因,因此需要新的治療方法。
“我們對此感到滿意 果醬 選擇重點介紹我們的 target-HTN 2 期試驗結果。這些結果表明,難以治療的高血壓具有潛在的變革性降低,肥胖者尤其如此,衆所周知,他們的醛固酮升高,心血管發病率和死亡率過高。” Mineralys首席醫學官戴維·羅德曼醫學博士說。“我們認爲,這項試驗證實了肥胖、醛固酮分泌過多與高血壓之間的聯繫。根據在target-HTN中觀察到的有益反應,我們最近啓動的關鍵計劃爲便於識別可能從lorundrostat等醛固酮靶向療法中受益的患者奠定了基礎。”
試驗結果支持進一步研究lorundrostat作爲uhTN的治療方法,包括該公司正在進行的用於治療uhTN和rhTN的lorundrostat的關鍵開發計劃。根據該計劃,該公司目前正在招收受試者參加關鍵的Advance-HTN試驗,並預計將在下半年啓動關鍵的Launch-HTN試驗,預計將分別在2024年上半年和2025年中期公佈頂線數據。
Target-HTN(NCT05001945)2期概念驗證試驗是一項在美國進行的隨機、雙盲、安慰劑對照、劑量範圍、多中心試驗。該試驗旨在評估口服氯侖卓司他用於治療uhTN和rhTN的劑量反應,該試驗旨在評估口服氯侖卓司他用於治療uhTN和rhTN的附加療法,對200名男性使用兩種或更多抗高血壓藥物進行穩定背景治療時的安全性、有效性、耐受性和劑量反應 18歲或以上的女性受試者。在高血壓受試者中,將五種活性劑量的洛倫卓司他(每天一次12.5mg QD、50mg QD、100mg QD、每天兩次 12.5mg [BID] 和25mg BID)與安慰劑進行了比較。藥代動力學、藥效學和反應數據表明,每天一次的給藥方案是最佳的。觀察到的不良事件包括血清鉀略有增加、估計的腎小球濾過率降低、尿路感染和高血壓,其中一個嚴重的不良事件可能與研究藥物有關,即低鈉血癥。